ArticleBiotechnology and bioengineering2026
Dynamic Immune Cell Composition, Phenotypes, and Signaling in an Engineered Metastatic Niche.
Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives.Journal of hematology & oncology · 2026Review
- Dynamic Immune Cell Composition, Phenotypes, and Signaling in an Engineered Metastatic Niche.Biotechnology and bioengineering · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In breast cancer patients, metastasis is the stage of disease where prognosis significantly worsens. However, the timing at which metastasis initiates and the location of metastatic lesions in an organ are stochastic, limiting the timely identification of disease and the administration of treatments. Herein, we employ a synthetic metastatic niche comprised of a microporous scaffold to investigate the dynamic immune processes associated with metastatic progression. Upon implantation, the porous scaffold is infiltrated with immune cells and recruits tumor cells. We have previously reported stable tumor cell numbers in the scaffold, suggesting a state of metastatic dormancy. Towards understanding dormancy, we investigated the immune cell dynamics at the scaffold, including neutrophils, monocytes, and dendritic cells, and compared these changes to the lungs, the native metastatic niche in this model. The cell phenotypes within the scaffold microenvironment are initially polarized toward an anti-tumor phenotype and become progressively more pro-tumor with disease progression, similar to the lung microenvironment. However, the phenotypes at the scaffold are consistently less pro-tumor than the phenotypes in the lung, consistent with the lung supporting tumor cell expansion and the scaffold exhibiting dormancy. Signaling pathways identified from the analysis are consistent with the changing innate cell phenotypes, with macrophages having a significant role during the early responses and neutrophils dominating the latter stages of disease. Collectively, the scaffold captures the immune dynamics during disease progression and the signaling that underlies stable tumor cell numbers, providing a tool for investigating the mechanisms of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.